MNKD Q4 2021 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-32.1% YoY

Gross Profit

$1M8.6% margin

Operating Income

-$24M-191.5% margin

Net Income

-$28M-224.2% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-43.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$321M

Total Liabilities

$531M

Stockholders' Equity

-$209M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$18M	-32.1%
Gross Profit	$1M	$12M	-91.1%
Operating Income	-$24M	-$24M	-0.9%
Net Income	-$28M	-$26M	-6.2%

Revenue Segments

Product

$11M61%

License And Service

$7M39%